|Mr. John F. Crowley||Chairman and Chief Exec. Officer||1.72M||N/A||51|
|Mr. Bradley L. Campbell||Pres and Chief Operating Officer||657.99k||N/A||42|
|Mr. William D. Baird III||Chief Financial Officer||543.52k||19.43k||46|
|Dr. Hung Do Ph.D.||Chief Science Officer||502.32k||N/A||50|
|Dr. Jay A. Barth M.D.||Chief Medical Officer||782.29k||N/A||54|
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. Its principal product is the migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which has completed two global Phase III registration studies. The company is also developing SD-101, which is in Phase III clinical study for the treatment of the genetic connective tissue disorder epidermolysis bullosa; and AT3375 to treat Parkinson's disease. It is conducting a Phase 1/2 clinical study of ATB200-02 to investigate pompe treatment paradigm in pompe patients. The company has strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
Amicus Therapeutics, Inc.’s ISS Governance QualityScore as of January 1, 2018 is 6. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 7; Compensation: 7.